Phase I study of azacitidine following donor lymphocyte infusion for relapsed acute myeloid leukemia post allogeneic stem cell transplantation
详细信息 查看全文
- 作者：Armin Ghobadi ; MDa ; aghobadi@wustl.edu" class="auth_mail" title="E-mail the corresponding author ; Jaebok Choi ; PhDa ; Mark A. Fiala ; BS ; CCRPa ; Theresa Fletcher ; MSa ; Jingxia Liu ; PhDb ; Linda G. Eissenberg ; PhDa ; Camille Abboud ; MDa ; Amanda Cashen ; MDa ; Ravi Vij ; MDa ; Mark A. Schroeder ; MDa ; Iskra Pusic ; MDa ; Keith Stockerl-Goldstein ; MDa ; Meagan Jacoby ; MD ; PhDa ; Geoffrey Uy ; MDa ; John DiPersio ; MD ; PhDa ; Peter Westervelt ; MD ; PhDa
- 关键词：Allogeneic stem cell transplantation ; Acute myeloid leukemia ; Donor lymphocyte infusion ; Azacitidine ; Graft versus host disease
- 刊名：Leukemia Research
- 出版年：2016
- 出版时间：October 2016
- 年：2016
- 卷：49
- 期：Complete
- 页码：1-6
- 全文大小：1217 K
文摘
- •
Azacitidine (AzaC) on days 4, 6, 8, and 10 post DLI is safe.
- •
AzaC early post DLI can potentially prevent GVHD.
- •
The effect of AzaC post DLI on GVHD and GVL should be studied in a larger study.